BIGBEAR
PHARMACEUTICALS
Cobimetinib first received marketing authorization in the European Union in 2015. It is a highly selective, reversible allosteric inhibitor of mitogen-activated protein kinase (MEK) 1/2.
AuthenticGuaranteeFast DeliveryPrivacy November 10, 2015 -- The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat a···【Read More】
Update: 28 Feb,2026Source: Haiou HealthViews: 71
1-Nov-2022 -- Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK ···【Read More】
Update: 28 Feb,2026Source: Haiou HealthViews: 74
Copyright2024@ BIGBEAR All right reserved BIGBEAR
